Iovance Biotherapeutics, Inc. (IOVA)
8.60
+0.46
(+5.65%)
USD |
NASDAQ |
Sep 11, 16:00
8.615
+0.02
(+0.17%)
After-Hours: 20:00
Iovance Biotherapeutics Price to Book Value : 5.293 for Sept. 11, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 5.293 |
| September 10, 2026 | 5.010 |
| September 09, 2026 | 5.188 |
| September 08, 2026 | 5.354 |
| September 04, 2026 | 5.410 |
| September 03, 2026 | 5.354 |
| September 02, 2026 | 5.305 |
| September 01, 2026 | 5.096 |
| August 31, 2026 | 5.028 |
| August 28, 2026 | 4.930 |
| August 27, 2026 | 5.083 |
| August 26, 2026 | 4.973 |
| August 25, 2026 | 5.194 |
| August 24, 2026 | 4.960 |
| August 21, 2026 | 5.102 |
| August 20, 2026 | 5.533 |
| August 19, 2026 | 4.917 |
| August 18, 2026 | 4.326 |
| August 17, 2026 | 4.369 |
| August 14, 2026 | 4.296 |
| August 13, 2026 | 4.012 |
| August 12, 2026 | 4.148 |
| August 11, 2026 | 3.994 |
| August 10, 2026 | 3.939 |
| August 07, 2026 | 3.902 |
| Date | Value |
|---|---|
| August 06, 2026 | 3.822 |
| August 05, 2026 | 2.671 |
| August 04, 2026 | 2.683 |
| August 03, 2026 | 2.656 |
| July 31, 2026 | 2.505 |
| July 30, 2026 | 2.886 |
| July 29, 2026 | 2.806 |
| July 28, 2026 | 2.892 |
| July 27, 2026 | 3.016 |
| July 24, 2026 | 3.071 |
| July 23, 2026 | 3.157 |
| July 22, 2026 | 3.182 |
| July 21, 2026 | 3.372 |
| July 20, 2026 | 3.089 |
| July 17, 2026 | 3.077 |
| July 16, 2026 | 2.868 |
| July 15, 2026 | 2.917 |
| July 14, 2026 | 2.419 |
| July 13, 2026 | 2.486 |
| July 10, 2026 | 2.603 |
| July 09, 2026 | 2.689 |
| July 08, 2026 | 2.634 |
| July 07, 2026 | 2.677 |
| July 06, 2026 | 2.579 |
| July 02, 2026 | 2.652 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Amgen, Inc. | 17.45 |
| AVITA Medical, Inc. | -- |
| Halozyme Therapeutics, Inc. | 85.17 |
| Neurocrine Biosciences, Inc. | 4.297 |
| Editas Medicine, Inc. | 3.937 |
Price to Book Value Related Metrics
| PS Ratio | 10.85 |
| Price | 8.60 |
| Earnings Yield | -8.39% |
| Market Cap | 3.896B |